Clinical trial · Observational
The Effect of Dexmedetomidine of the Immune System
The Effect of Dexmedetomidine on Immunological Parameters of Women Undergoing Breast Cancer Surgery
NCT01692210CI-TRIAL-00020461completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this research study is to learn about how dexmedetomidine (a standard of care sedative) affects your immune system (your defenses against cancer) by measuring your white blood cell levels before and after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Blood Draw Pre and Post Surgery
- description
- Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Pre and Post Surgical Lymphocyte Counts
- timeFrame
- 2 days
- description
- Lymphocyte counts determined by flow-cytometry and their function by cytotoxicity assays performed in the laboratory using samples obtained before and the morning after surgery. Patients who experience a reduction of less than 50% of their preoperative natural killer cell (NKC) activity considered as a success.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 3.1.1 - Women undergoing unilateral mastectomy for malignancy at MD Anderson Cancer Center. 3.1.2 - Patients 18 years of age and older. There will be no upper age restriction. 3.1.3 - Patients must sign a study-specific consent form. Exclusion Criteria: 3.2.1 - ASA 4 3.2.2 - Contraindication to the use of dexmedetomidine. 3.2.2.1. Decompensated congestive heart failure. 3.2.2.2. Second and third degree heart block. 3.2.2.2. Known allergy to dexmedetomidine or any of the medications used in the study 3.2.3 - Patients taking clonidine for treatment of arterial hypertension. 3.2.4 - Patients that are pregnant. 3.2.5 - Patients taking opioids at the time of surgery. 3.2.6 - Patients having plastic surgical reconstruction. 3.2.7 - Recent chemotherapy (\< 4 weeks). 3.2.8 - Active autoimmune or immunological disease including but not limited to systemic lupus erythematous, rheumatoid arthritis and Sjogren's disease 3.2.9 - Patient refusal to participate in the study.
References
Publications (0)
Data not yet available
No reference posted for this study.